Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-334P (RNA, U6 small nuclear 334, pseudogene) is a pseudogene in the human genome derived from the small nuclear RNA U6 gene family[2]. Like other U6-derived pseudogenes, RNU6-334P is a non-coding sequence that does not produce a functional RNA or protein product, and it lacks known biological activity or therapeutic relevance[2][5]. The parent molecule, U6 small nuclear RNA (snRNA), is an essential component of the spliceosome and catalyzes pre-mRNA splicing in eukaryotic cells[1][3]. However, the pseudogene variant RNU6-334P itself is considered a genomic relic with no known physiological function, disease association, or role as a therapeutic target[2][5]. Pseudogenes like RNU6-334P are typically classified under "other" for molecular classification, and while they may provide insight into evolutionary mechanisms or genome structure, they do not have active roles in gene regulation, disease, or drug response[2][5]. No drugs, biomarkers, or disease mechanisms are linked to this pseudogene, and there are no known safety concerns associated with its presence. There is also no canonical, functional protein or RNA produced from RNU6-334P[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 334, pseudogene (RNU6-334P).